Resistin - The role in development of insulin resistance - Facts and controversy;Rezystyna - Rola w rozwoju insulinooporności - Fakty i kontrowersje

Nadcisnienie Tetnicze

Volumn 10, Issue 4, 2006, Pages 301-306

  Szulińska, Monika ^a,b   Pupek Musialik, Danuta ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b Katedra i Klinika Chorob Wewnetrznych   (Poland)

Author keywords

Inflammatory; Insulin resistance; Obesity; Resistin

Indexed keywords

RESISTIN;

BODY FAT DISTRIBUTION; CHROMOSOME 19; EXON; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; REVIEW;

EID: 33750383269     PISSN: 14285851     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Report of a WHO Consultation on Obesity. Preventing and Managing the Global Epidemic. Division of noncomunicable Diseases. World Health Organization. Geneva 3-5 June 1997. WHO/NUT/NCD 1998.
2. Must A., Spadano J., Coakley E., Field A., Colditz G., Dietz W. The disease burden associated with overweight and obesity. JAMA 1999; 282: 1523-1529.
3. Report of a WHO. Consultation on Obesity. Obesity. Preventing and Managing the Global Epidemic. Division of non-communicable Diseases. WHO. Geneva 3-5 June 1997.
4. The World Health Report 2002. Reducing Risks, Promoting Health Life, Geneva 2002.
5. Manson J., Willett W., Stampfer M. i wsp. Body weight and mortality among women. N. Engl. J. Med. 1995; 333: 677-685.
6. Schmitz-Peiffer C. Signalling aspects of insulin resistance in skeletal muscle mechanisms induced by lipid oversupply. Cellular Signaling 2000; 12: 583-594.
7. Bjornholm M., Al-Khalili L., Dicker A. i wsp. Insulin signal transduction and glucose transport in human adipocytes: effects of obesity and low calorie diet. Diabetologia 2002; 45 (8): 1128-1135.
8. Krief S., Lonqvist F., Raimbault S. i wsp. Tissue distribution of beta 3 adrenergic receptor mRNA in man. J. Clin. Invest. 1993; 91: 344-349.
9. Lonqvist F., Thorne A., Nilsell K., Hoffstedt J., Arner P. A pathogenic role of visceral fat beta-3 adrenoreceptors in obesity. J. Clin. Invest. 1995; 95: 1109-1116.
10. Ferrano R., Eckel H., Larson D. i wsp. Relationship between skeletal muscle lipoprotein lipase activity and 24 hour malnutritient oxidation J. Clin. Invest. 1993; 92: 441-445.
11. Lapidus L., Bengtesson B., Larsson B., Pennert K., Rybo E., Sjostrom D. Distribution of adipose tissue and risks of cardiovascular disease and death: a 12-year follow up of participants in the population study of women in Gotheborg, Sweden. BMJ 1984; 289: 1261-1263.
12. Serrero G., Lepak N. Endocrine and paracrine negative regulators of adipose differentiation. Int. J. Obes. 1996; 20 (3): 58-64.
13. Fruhbeck G., Gomez-Ambrosi J., Jose Muruzabal F., Burrell M. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am. J. Physiol. Endocrinol. Metab. 2001; 280 (6): 827-847.
14. Wang H., Chu W., Hemphill C., Elbein S. Human resistin gene: molecular scanning and evaluation of association with insulin sensitivity and type 2 diabetes in Caucasians. J. Clin. Endocr. Metab. 2002; 87: 2520-2524.
15. Steppan C., Balley S., Bhat S. i wsp. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312.
16. Holcomb I., Kabakoff R., Chan B. i wsp. FIZZ1, a novel cysteine-rich secreted protein associated with inflammation, defines a new gene family. EMBO J. 2000; 19: 4046-4055.
17. Berger A.: Resistin: a new hormon that links obesity with type 2 diabetes. BMJ 2001; 322: 193.
18. McTernan G., McTernan P., Harte A., Levick P., Barnett A., Kumar S. Resistin, central obesity, and type 2 diabetes. Lancet 2002; 359: 46-47.
19. Qian H., Gingerich R., Mistry J. Differences in the expression pattern of resistin protein in the serum and adipose tissue of ob/ob mice. Diabetes 2003; 52 (1): A86-A87.
20. Steppan C., Brown E., Wrihgt C. i wsp. A family of tissue-specific resistin-like molecules. Proc. Natl. Acad. Sci. USA 2001; 98: 502-506.
21. Way J., Gorgun C., Tong Q. i wsp. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisime proliferator- activator receptor gamma-agonists. J. Biol. Chem. 2001; 276: 25651-25653.
22. Shuldiner A., Yang R., Gong D. Resistin-obesity and insulin resistance -the emerging role of the adipocyte as an endocrine organ. N. Engl. J. Med. 2001; 345: 1345-1346.
23. Rangwala S., Rich A., Rhoades B. i wsp. Abnormal glucose homeostasis due to chronic hyperresistinemia. Diabetes 2004; 53: 1937-1941.
24. Banerjee R., Rangwala S., Shapiro J. i wsp. Regulation of fasted blood glucose by resistin. Science 2004; 303: 1195-1198.
25. Steppan C., Wang J., Whiteman E., Birnbaum M., Lazar M. Activation of SOCS-3 by resistin. Mol. Cell Biol. 2005; 25 (4): 1569-75.
26. Degawa-Yamauchi M., Bovenkerk J., Juliar B. i wsp. Serum resistin (FIZZ3) protein is increased in obese humans. J. Clin. Endocr. Metab. 2003; 88: 5452-5455.
27. Vozarova De Courten B., Degawa-Yamauchi M., Considine R.V., Tataranni P.A. High serum resistin is associated with an increase in adiposity but not a worsening of insulin resistance in Pima Indian. Diabetes 2004; 53 (9): 1279-1284.
28. Hasegawa G., Ohta M., Shigeta H. i wsp. Plasma concentrations of resistin in type 2 diabetic patients. Diabetes 2003; 52 (1): A82-A83.
29. Lee J.H., Chan J.L., Yiaannahours N. i wsp. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J. Clin. Endocrin. Metabol. 2003; 88 (10): 4848-4856.
30. Cao H., Hegele R. Single nucleotide polymorphisms of the resistin (RSTN) gene. J. Hum. Genet. 2001; 46: 553-555.
31. Tan M., Chang S., Chang D., Tsai J., Lee Y. Association of Resistin Gene 3′-Untranslated Region +62G→A Polymorphism with Type 2 Diabetes and Hypertension in a Chinese Population. J. Clin. Endocrin. Metabol. 2003; 88 (3): 1258-263.
32. Weyer C., Yudkin J., Stehouwer C., Schalkwijk C., Pratley R., Tataranni P. Humoral markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians. Atherosclerosis 2002; 161: 233-242.
33. Shetty G., Economides P., Horton E., Mantzoros C., Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 2004; 27: 2450-2457.
34. Lehrke M., Reilly M., Millington S., Iqbal N., Lazar M. An inflammatory cascade leading to hyperresistinemia in humans. PIoSL. Med. 2004; 1 (2): 161-168.
35. Diez J., Iglesias P., Fernandez-Reyes M. i wsp. Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease. Clin. Endocrinol. 2005; 62 (2): 242-249.
36. Gomez-Ambrosi J., Fruhbeck G. Do resistin and resistin-like molecules also link obesity to inflammatory diseases? Ann. Intern. Med. 2001; 135: 306-307.
37. Axelsson J., Heimburger O., Lindholm B. Adipose tissue and its relation to inflammation the role of adipokines. J. Ren. Nutr. 2005; 15(1): 131-136.